Therapeutic Plasma Exchange for a Critically Ill Late Preterm Infant with Multisystem Inflammatory Syndrome of Children: A Case Report and Review of the Literature

J Pediatr Infect Dis
DOI: 10.1055/s-0044-1789607

1   Department of Neonatology, Istanbul Kanuni Sultan Suleyman Research and Training Hospital, University of Health Sciences, Istanbul, Türkiye

,

1   Department of Neonatology, Istanbul Kanuni Sultan Suleyman Research and Training Hospital, University of Health Sciences, Istanbul, Türkiye

,

1   Department of Neonatology, Istanbul Kanuni Sultan Suleyman Research and Training Hospital, University of Health Sciences, Istanbul, Türkiye

,

2   Pediatrics, Pediatric Intensive Care Unit Department, Istanbul Kanuni Sultan Suleyman Research and Training Hospital, University of Health Sciences, Istanbul, Türkiye

,

3   Pediatric Emergency Department, Istanbul Kanuni Sultan Suleyman Research and Training Hospital, University of Health Sciences, Istanbul, Türkiye

,

1   Department of Neonatology, Istanbul Kanuni Sultan Suleyman Research and Training Hospital, University of Health Sciences, Istanbul, Türkiye

› Author Affiliations Funding This research did not receive any grant from the public, commercial, or not-for-profit sector funding agencies.
› Further Information Also available at   SFX Search  Buy Article Permissions and Reprints Abstract

Multisystem inflammatory syndrome of children (MIS-C) is a clinical picture that entered the medical nomenclature after the coronavirus disease 2019 pandemic. Although it primarily affects older children, there have been a limited number of cases reported during the neonatal period. Herein we present a patient, a late preterm infant, with severe MIS-C-related cerebral sinus venous thrombosis who was successfully treated with therapeutic plasma exchange. Practitioners can consider therapeutic plasma exchange as a safe and effective option for the treatment of critically ill MIS-C cases.

Keywords COVID-19 - MIS-C - newborn - therapeutic plasma exchange Ethics Approval

Institutional Review Board approval was received from local Ethics Committee of our university.


Informed Consent

Informed consent was obtained from the parents prior to participation in the study.


Data Availability

All data of the patient are stored in the data recording system of our hospital.

Publication History

Received: 18 January 2024

Accepted: 06 August 2024

Article published online:
29 August 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
References 1 Deng CX. The global battle against SARS-CoV-2 and COVID-19. Int J Biol Sci 2020; 16 (10) 1676-1677 2 Centers for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). CDC Health Alert Network; 2020. 3 Melgar M, Lee EH, Miller AD. et al. Council of State and Territorial Epidemiologists/CDC surveillance case definition for multisystem inflammatory syndrome in children associated with SARS-CoV-2 infection - United States. MMWR Recomm Rep 2022; 71 (04) 1-14 4 Centers for Disease Control and Prevention (CDC). CSTE. https://ndc.services.cdc.gov/case-definitions/multisystem-inflammatory-syndrome-in-children-mis-c-2023/ 5 More K, Aiyer S, Goti A. et al. Multisystem inflammatory syndrome in neonates (MIS-N) associated with SARS-CoV2 infection: a case series. Eur J Pediatr 2022; 181 (05) 1883-1898 6 Zuccotti G, Calcaterra V, Mannarino S. et al. Six-month multidisciplinary follow-up in multisystem inflammatory syndrome in children: an Italian single-center experience. Front Pediatr 2023; 10: 1080654 7 De Rose DU, Pugnaloni F, Calì M. et al. Multisystem inflammatory syndrome in neonates born to mothers with SARS-CoV-2 infection (MIS-N) and in neonates and infants younger than 6 months with acquired COVID-19 (MIS-C): a systematic review. Viruses 2022; 14 (04) 750 8 Jiang L, Tang K, Levin M. et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis 2020; 20 (11) e276-e288 9 Mascarenhas D, Goyal M, Haribalakrishna A, Nanavati R, Ish P, Kunal S. Multisystem inflammatory syndrome in neonates (MIS-N): a systematic review. Eur J Pediatr 2023; 182 (05) 2283-2298 10 Pawar R, Gavade V, Patil N. et al. Neonatal multisystem inflammatory syndrome (MIS-N) associated with prenatal maternal SARS-CoV-2: a case series. Children (Basel) 2021; 8 (07) 572 11 Sözeri B, Çağlayan Ş, Atasayan V. et al. The clinical course and short-term health outcomes of multisystem inflammatory syndrome in children in the single pediatric rheumatology center. Postgrad Med 2021; 133 (08) 994-1000 12 Porosnicu TM, Sirbu IO, Oancea C. et al. The impact of therapeutic plasma exchange on inflammatory markers and acute phase reactants in patients with severe SARS-CoV-2 infection. Medicina (Kaunas) 2023; 59 (05) 867 13 Ebermeyer T, Hequet O, Berard F. et al. The efficacy of therapeutic plasma exchange in COVID-19 patients on endothelial tightness in vitro is hindered by platelet activation. Front Cardiovasc Med 2023; 10: 1094786 14 Durak C, Guney Sahin E, Can YY, Varol F. Retrospective evaluation of therapeutic plasma exchange treatment in a pediatric intensive care unit: single-center experience. Artif Organs 2023; 47 (09) 1464-1471 15 Al-Hashami S, Khamis F, Al-Yahyay M. et al. Therapeutic plasma exchange: a potential therapeutic modality for critically ill adults with severe acute respiratory syndrome coronavirus 2 infection. J Clin Apher 2022; 37 (06) 563-572 16 Atay G, Hasbal C, Türk M, Erdoğan S, Sözeri B. The role of therapeutic plasma exchange (TPE) in multisystem inflammatory syndrome in children (MIS-C). Children (Basel) 2021; 8 (06) 498 17 Katlan B, Kesici S, Karacanoğlu D. et al. Early is superior to late plasma exchange for severe multisystem inflammatory syndrome in children. J Clin Apher 2022; 37 (03) 281-291 18 Dakay K, Cooper J, Bloomfield J. et al. Cerebral venous sinus thrombosis in COVID-19 infection: a case series and review of the literature. J Stroke Cerebrovasc Dis 2021; 30 (01) 105434 19 Lindan CE, Mankad K, Ram D. et al; ASPNR PECOBIG Collaborator Group. Neuroimaging manifestations in children with SARS-CoV-2 infection: a multinational, multicentre collaborative study. Lancet Child Adolesc Health 2021; 5 (03) 167-177 20 Trapani S, Rubino C, Lasagni D. et al. Thromboembolic complications in children with COVID-19 and MIS-C: a narrative review. Front Pediatr 2022; 10: 944743 21 Whitworth H, Sartain SE, Kumar R. et al. Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C. Blood 2021; 138 (02) 190-198 22 Davies P, Evans C, Kanthimathinathan HK. et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet Child Adolesc Health 2020; 4 (09) 669-677 23 Aguilera-Alonso D, Murias S, Martínez-de-Azagra Garde A. et al; EPICO-AEP Working Group. Prevalence of thrombotic complications in children with SARS-CoV-2. Arch Dis Child 2021; 106 (11) 1129-1132 24 Di Profio E, Leone A, Vizzuso S. et al. Longitudinal anthropometry and body composition in children with SARS-CoV-2-associated multisystem inflammatory syndrome. J Pediatr Gastroenterol Nutr 2023; 76 (04) 505-511 25 National Institutes of Health (NIH). Treatment considerations for children with MIS-C. Accessed February 29, 2024 at: https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-children/hospitalized-children-therapeutic-management-of-mis-c/
 

Comments (0)

No login
gif